• IBA posted H1 2026 net sales up 6% to EUR 323.7 million, with gross margin widening 4.2 percentage points to 33.7%.
• Net result swung to profit of EUR 9.3 million, yielding EPS of EUR 0.32.
• Adjusted EBIT rose 66% to EUR 17.6 million, driven by improved execution and profitability mix in Proton Therapy.
• Equipment order intake jumped to EUR 176 million, with IBA Clinical more than doubling to EUR 148 million on five rooms sold.
• FY 2026 adjusted EBIT guidance reiterated at at least EUR 32 million, with management citing continued momentum in Proton Therapy and RadioPharma Solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBA - Ion Beam Applications SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270100OMX_____CNEWS_EN_GNW1001259518_en) on August 27, 2026, and is solely responsible for the information contained therein.